RANKL inhibition with osteoprotegerin increases bone strength in ovariectomized rats
11/08/2009 in Pre-clinical dataOvariectomy results in bone loss caused by increased bone resorption. RANKL is an essential mediator of bone resorption. The purpose of a recent study [1] was to examine whether the RANKL inhibitor osteoprotegerin (OPG) would preserve bone volume, density, and strength in ovariectomized rats. Rats were ovariectomized or sham-operated at 3 mo of age. Sham controls were treated for 6 wk with vehicle. Ovariectomized rats were treated with vehicle or human OPG-Fc (10 mg/kg, 2/wk). Serum RANKL and TRACP5b, an osteoclast marker, was measured by ELISA. BMD of lumbar vertebrae (L1–L5) and distal femur was measured by DXA. Right distal femurs were processed for bone histomorphometry. Left femurs and the fifth lumbar vertebra (L5) were analyzed by µCT and biomechanical testing, and L6 was analyzed for ash weight.
Read the rest of this entry »



Most used keywords
β-catenin age BMD bone bone density bone density test bone formation bone fracture bone loss bone marrow bone remodeling bone resorption bone strength breast cancer calcium cardiovascular cardiovascular disease cell cell bone marrow cholesterol Clinical data diabetes disease epidemiology fracture fracture risk FRAX heart heart disease hip fracture mesenchymal stem cells neuromedin U osteoblast osteoblast differentiation osteoclast osteoporosis osteoprotegerin osterix ovariectomy RANKL residual lifetime risk risk factors sclerotin survival weight loss